Pre-existing inflammatory disease predicts cutaneous immunotherapy toxicity development: A multi-institutional cohort study

To the Editor: Though immune checkpoint inhibitors (ICIs) have considerably improved patient outcomes, they are associated with morbid and potentially life-threatening immune-related adverse events (irAEs). As a result of the immune-mediated nature of these toxicities, and despite recent evidence that ICI recipients with pre-existing inflammatory diseases (pIDs) are not at increased risk of mortality,1,2 patients with pIDs have been largely excluded from ICI clinical trials, and data on toxicity development in this population are lacking.